# VI-1121 for the Treatment Alzheimer's Disease

> **NCT01428362** · PHASE2 · COMPLETED · sponsor: **VIVUS LLC** · enrollment: 61 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** VI-1121
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01428362
- **Lead sponsor:** VIVUS LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2013-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428362, "VI-1121 for the Treatment Alzheimer's Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01428362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*